US 12,320,799 B2
Methods of measuring signaling pathway activity for selection of therapeutic agents
Lance Gavin Laing, Orono, MN (US); and Brian Francis Sullivan, Medina, MN (US)
Assigned to Celcuity Inc., Minneapolis, MN (US)
Filed by Celcuity Inc., Minneapolis, MN (US)
Filed on Apr. 13, 2022, as Appl. No. 17/720,067.
Application 17/720,067 is a division of application No. 16/116,392, filed on Aug. 29, 2018, granted, now 11,333,659.
Application 16/116,392 is a continuation of application No. PCT/US2018/022936, filed on Mar. 16, 2018.
Claims priority of provisional application 62/587,572, filed on Nov. 17, 2017.
Claims priority of provisional application 62/473,936, filed on Mar. 20, 2017.
Prior Publication US 2023/0125427 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 31/00 (2006.01); A61K 31/407 (2006.01); A61K 31/4709 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/5011 (2013.01) [A61K 31/407 (2013.01); A61K 31/4709 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); G01N 33/5044 (2013.01); G01N 33/57484 (2013.01); G01N 33/5017 (2013.01); G01N 33/5041 (2013.01); G01N 2333/71 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7028 (2013.01)] 11 Claims
 
1. A method of treating a human subject diagnosed with cancer, the method comprising:
administering to the subject at least one targeted therapeutic that targets a signaling pathway selected from the group consisting of Protein kinase B (AKT), Phosphoinositide 3-kinase (PI3K), MAPK/ERK kinase (MEK), Extracellular signal-regulated kinase (ERK) and Mammalian target of rapamycin (mTOR), wherein
the at least one targeted therapeutic is therapeutically active in said signaling pathway in the subject's cancer cells by a method comprising:
culturing a sample comprising viable cancer cells obtained from the subject;
contacting the sample with at least one triplet set of agents, each triplet set comprised of a first agent targeted therapeutic and at least two second agent activators that are known to selectively affect the same signaling pathway the targeted therapeutic is intended to address, so as to upregulate or downregulate the signaling pathway as measured by an effect on cell adhesion or attachment, to produce a sample contacted with at least one triplet set of agents;
continuously measuring cell adhesion or attachment of the viable cancer cells in the sample contacted with the at least one triplet set of agents, relative to a sample of viable cancer cells obtained from the subject that is contacted with the first agent targeted therapeutic or each of the second agent activators alone;
determining an output value, expressed as a percentage, for the at least one triplet set of agents that characterizes whether a change in cell adhesion or attachment has occurred in the sample contacted with the triplet set of agents, as compared to the sample contacted with the first agent targeted therapeutic or the second agent activators alone; and
administering to the subject the at least one targeted therapeutic that affects the same signaling pathway as the first agent targeted therapeutic from the triplet set of agents when the output value percentage is greater than 50% indicating the targeted therapeutic is therapeutically active in the cell signaling pathway of the subject's cancer cells.